Review



proteinchip peptide  (Bio-Rad)


Bioz Verified Symbol Bio-Rad is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    Bio-Rad proteinchip peptide
    Progression of specific intensity peaks within mass profiles during Etanercept treatment. Shown is the progression of intensities (relative units) of the 4326 Da (A), 6632 Da (B) and 133977 Da (C) peaks of the mass profiles over time. W0, W12 and W24 correspond to duration of Etanercept treatment expressed in weeks. Samples exhibiting a significant difference for C (healthy controls) vs W0, W0 vs W12 and W0 vs W24 are shown. Horizontal lines correspond to the mean of the 10 samples for each condition. P-values were calculated using the non-parametric Mann-Whitney test when comparing C to W0 (unpaired data), and the non-parametric Wilcoxon signed-rank test when comparing W0 to W12, or W0 to W24 (paired data). *Statistically significant difference between C and W0. **Statistically significant difference between W0 and W12, or between W0 and W24. The 4.3 and 134 kDa masses were detected using fraction 2, and the 6.6 kDa mass was detected using fraction 4. <t>ProteinChip®,</t> matrix and laser intensity conditions are detailed in Table 2.
    Proteinchip Peptide, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 93/100, based on 6 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/proteinchip peptide/product/Bio-Rad
    Average 93 stars, based on 6 article reviews
    proteinchip peptide - by Bioz Stars, 2026-05
    93/100 stars

    Images

    1) Product Images from "Targeting TNFα in severe psoriasis-mass spectrometry reveals a time-dependent specific inhibition of Factor H in responding patients"

    Article Title: Targeting TNFα in severe psoriasis-mass spectrometry reveals a time-dependent specific inhibition of Factor H in responding patients

    Journal: American Journal of Translational Research

    doi:

    Progression of specific intensity peaks within mass profiles during Etanercept treatment. Shown is the progression of intensities (relative units) of the 4326 Da (A), 6632 Da (B) and 133977 Da (C) peaks of the mass profiles over time. W0, W12 and W24 correspond to duration of Etanercept treatment expressed in weeks. Samples exhibiting a significant difference for C (healthy controls) vs W0, W0 vs W12 and W0 vs W24 are shown. Horizontal lines correspond to the mean of the 10 samples for each condition. P-values were calculated using the non-parametric Mann-Whitney test when comparing C to W0 (unpaired data), and the non-parametric Wilcoxon signed-rank test when comparing W0 to W12, or W0 to W24 (paired data). *Statistically significant difference between C and W0. **Statistically significant difference between W0 and W12, or between W0 and W24. The 4.3 and 134 kDa masses were detected using fraction 2, and the 6.6 kDa mass was detected using fraction 4. ProteinChip®, matrix and laser intensity conditions are detailed in Table 2.
    Figure Legend Snippet: Progression of specific intensity peaks within mass profiles during Etanercept treatment. Shown is the progression of intensities (relative units) of the 4326 Da (A), 6632 Da (B) and 133977 Da (C) peaks of the mass profiles over time. W0, W12 and W24 correspond to duration of Etanercept treatment expressed in weeks. Samples exhibiting a significant difference for C (healthy controls) vs W0, W0 vs W12 and W0 vs W24 are shown. Horizontal lines correspond to the mean of the 10 samples for each condition. P-values were calculated using the non-parametric Mann-Whitney test when comparing C to W0 (unpaired data), and the non-parametric Wilcoxon signed-rank test when comparing W0 to W12, or W0 to W24 (paired data). *Statistically significant difference between C and W0. **Statistically significant difference between W0 and W12, or between W0 and W24. The 4.3 and 134 kDa masses were detected using fraction 2, and the 6.6 kDa mass was detected using fraction 4. ProteinChip®, matrix and laser intensity conditions are detailed in Table 2.

    Techniques Used: MANN-WHITNEY



    Similar Products

    proteinchip peptide  (Bio-Rad)
    93
    Bio-Rad proteinchip peptide
    Progression of specific intensity peaks within mass profiles during Etanercept treatment. Shown is the progression of intensities (relative units) of the 4326 Da (A), 6632 Da (B) and 133977 Da (C) peaks of the mass profiles over time. W0, W12 and W24 correspond to duration of Etanercept treatment expressed in weeks. Samples exhibiting a significant difference for C (healthy controls) vs W0, W0 vs W12 and W0 vs W24 are shown. Horizontal lines correspond to the mean of the 10 samples for each condition. P-values were calculated using the non-parametric Mann-Whitney test when comparing C to W0 (unpaired data), and the non-parametric Wilcoxon signed-rank test when comparing W0 to W12, or W0 to W24 (paired data). *Statistically significant difference between C and W0. **Statistically significant difference between W0 and W12, or between W0 and W24. The 4.3 and 134 kDa masses were detected using fraction 2, and the 6.6 kDa mass was detected using fraction 4. <t>ProteinChip®,</t> matrix and laser intensity conditions are detailed in Table 2.
    Proteinchip Peptide, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/proteinchip peptide/product/Bio-Rad
    Average 93 stars, based on 1 article reviews
    proteinchip peptide - by Bioz Stars, 2026-05
    93/100 stars
    		  Buy from Supplier
    proteinchip peptide mass calibration kit  (Bio-Rad)
    93
    Bio-Rad proteinchip peptide mass calibration kit
    Progression of specific intensity peaks within mass profiles during Etanercept treatment. Shown is the progression of intensities (relative units) of the 4326 Da (A), 6632 Da (B) and 133977 Da (C) peaks of the mass profiles over time. W0, W12 and W24 correspond to duration of Etanercept treatment expressed in weeks. Samples exhibiting a significant difference for C (healthy controls) vs W0, W0 vs W12 and W0 vs W24 are shown. Horizontal lines correspond to the mean of the 10 samples for each condition. P-values were calculated using the non-parametric Mann-Whitney test when comparing C to W0 (unpaired data), and the non-parametric Wilcoxon signed-rank test when comparing W0 to W12, or W0 to W24 (paired data). *Statistically significant difference between C and W0. **Statistically significant difference between W0 and W12, or between W0 and W24. The 4.3 and 134 kDa masses were detected using fraction 2, and the 6.6 kDa mass was detected using fraction 4. <t>ProteinChip®,</t> matrix and laser intensity conditions are detailed in Table 2.
    Proteinchip Peptide Mass Calibration Kit, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/proteinchip peptide mass calibration kit/product/Bio-Rad
    Average 93 stars, based on 1 article reviews
    proteinchip peptide mass calibration kit - by Bioz Stars, 2026-05
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    Progression of specific intensity peaks within mass profiles during Etanercept treatment. Shown is the progression of intensities (relative units) of the 4326 Da (A), 6632 Da (B) and 133977 Da (C) peaks of the mass profiles over time. W0, W12 and W24 correspond to duration of Etanercept treatment expressed in weeks. Samples exhibiting a significant difference for C (healthy controls) vs W0, W0 vs W12 and W0 vs W24 are shown. Horizontal lines correspond to the mean of the 10 samples for each condition. P-values were calculated using the non-parametric Mann-Whitney test when comparing C to W0 (unpaired data), and the non-parametric Wilcoxon signed-rank test when comparing W0 to W12, or W0 to W24 (paired data). *Statistically significant difference between C and W0. **Statistically significant difference between W0 and W12, or between W0 and W24. The 4.3 and 134 kDa masses were detected using fraction 2, and the 6.6 kDa mass was detected using fraction 4. ProteinChip®, matrix and laser intensity conditions are detailed in Table 2.

    Journal: American Journal of Translational Research

    Article Title: Targeting TNFα in severe psoriasis-mass spectrometry reveals a time-dependent specific inhibition of Factor H in responding patients

    doi:

    Figure Lengend Snippet: Progression of specific intensity peaks within mass profiles during Etanercept treatment. Shown is the progression of intensities (relative units) of the 4326 Da (A), 6632 Da (B) and 133977 Da (C) peaks of the mass profiles over time. W0, W12 and W24 correspond to duration of Etanercept treatment expressed in weeks. Samples exhibiting a significant difference for C (healthy controls) vs W0, W0 vs W12 and W0 vs W24 are shown. Horizontal lines correspond to the mean of the 10 samples for each condition. P-values were calculated using the non-parametric Mann-Whitney test when comparing C to W0 (unpaired data), and the non-parametric Wilcoxon signed-rank test when comparing W0 to W12, or W0 to W24 (paired data). *Statistically significant difference between C and W0. **Statistically significant difference between W0 and W12, or between W0 and W24. The 4.3 and 134 kDa masses were detected using fraction 2, and the 6.6 kDa mass was detected using fraction 4. ProteinChip®, matrix and laser intensity conditions are detailed in Table 2.

    Article Snippet: Mass calibration was performed with the ProteinChip® peptide calibrating kit (Bio-Rad, C10-00002).

    Techniques: MANN-WHITNEY